Docoh
Loading...

IMGN Immunogen

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days.

Company profile

Ticker
IMGN
Exchange
CEO
Mark Enyedy
Employees
Incorporated
Location
Fiscal year end
Former names
IMMUNOGEN INC
SEC CIK
IRS number
42726691

IMGN stock data

(
)

Calendar

30 Jul 21
1 Aug 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Immunogen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 239.54M 239.54M 239.54M 239.54M 239.54M 239.54M
Cash burn (monthly) 14.53M (positive/no burn) 9.12M 3.04M 14.63M 9.22M
Cash used (since last report) 15.87M n/a 9.96M 3.32M 15.97M 10.07M
Cash remaining 223.67M n/a 229.57M 236.22M 223.56M 229.47M
Runway (months of cash) 15.4 n/a 25.2 77.7 15.3 24.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jun 21 Renee Lentini Common Stock Grant Aquire A No No 5.52 1,683 9.29K 13,831
30 Jun 21 Ryll Thomas Common Stock Grant Aquire A No No 5.52 3,849 21.25K 84,714
30 Jun 21 Wingrove Theresa Common Stock Grant Aquire A No No 5.52 1,768 9.76K 77,518
30 Jun 21 Enyedy Mark J Common Stock Grant Aquire A No No 5.52 3,849 21.25K 432,866
30 Jun 21 Berkenblit Anna Common Stock Grant Aquire A No No 5.52 2,062 11.38K 105,401

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

91.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 210 205 +2.4%
Opened positions 33 41 -19.5%
Closed positions 28 19 +47.4%
Increased positions 72 56 +28.6%
Reduced positions 68 72 -5.6%
13F shares
Current Prev Q Change
Total value 2.34B 1.12B +110.0%
Total shares 182.24M 172.9M +5.4%
Total puts 426.1K 465.8K -8.5%
Total calls 580.5K 451.9K +28.5%
Total put/call ratio 0.7 1.0 -28.8%
Largest owners
Shares Value Change
Wellington Management 19M $153.93M -13.9%
Ra Capital Management 18.42M $149.18M 0.0%
BLK Blackrock 16.31M $132.07M +7.6%
Vanguard 14.31M $115.89M +1.1%
FMR 13.53M $109.63M +7.9%
Redmile 9.69M $78.47M -8.0%
Orbimed Advisors 9.13M $73.97M +257.6%
STT State Street 9.02M $73.09M +2.5%
Clearbridge Advisors 6.11M $49.48M -11.4%
AMP Ameriprise Financial 5.6M $45.32M +201.2%
Largest transactions
Shares Bought/sold Change
Orbimed Advisors 9.13M +6.58M +257.6%
AMP Ameriprise Financial 5.6M +3.74M +201.2%
Wellington Management 19M -3.08M -13.9%
Consonance Capital Management 703.79K -2.81M -80.0%
Renaissance Technologies 1.86M -2.37M -56.0%
Adage Capital Partners GP, L.L.C. 4.5M +2.03M +81.8%
Lombard Odier Asset Management 1.85M +1.85M NEW
Compagnie Lombard Odier SCmA 1.85M +1.85M NEW
Marshall Wace North America 32.57K -1.54M -97.9%
Citadel Advisors 216.48K -1.52M -87.5%

Financial report summary

?
Management Discussion
  • In the second quarter and first half of 2021, total revenues increased $1.9 million and $4.3 million, respectively, compared to the second quarter and first half of 2020, driven by increases in non-cash royalty revenue, partially offset by decreases in license and milestone fees, both of which are discussed further below.
  • Kadcyla is a marketed ADC resulting from one of our development and commercialization licenses with the Roche Group, through its Genentech unit. We receive royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In the second quarter and first half of 2021, non-cash royalty revenue increased $2.6 million and $5.2 million, respectively, compared to the second quarter and first half of 2020, driven primarily by increases in net sales of Kadcyla due to market expansion. We sold our rights to receive royalty payments on the net sales of Kadcyla through two separate transactions in 2015 and 2019. Following the 2019 transaction, OMERS, the defined benefit pension plan for municipal employees in the Province of Ontario, Canada, is entitled to receive all of these royalties. See further details regarding the royalty obligation in Note E, “Liability Related to Sale of Future Royalties,” to our consolidated financial statements included in this report.
  • The amount of license and milestone fees we earn is directly related to the number of our collaborators, the advancement of product candidates covered by the agreements with our collaborators, and the overall success in the clinical trials of these product candidates. As such, the amount of license and milestone fees may vary significantly from quarter to quarter and year to year. License and milestone fee revenue decreased $0.7 million in the second quarter of 2021 compared to the second quarter of 2020 and decreased $0.8 million in the first half of 2021 compared to the first half of 2020, primarily due to the recognition of $0.9 million of previously deferred revenue in the second quarter and first half of 2020 related to the right to future technological improvements upon termination by Takeda of its license agreement.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: compelling, critical, duration, median, oral, PICCOLO, Restated, strategy, upcoming
Removed: acquire, activated, ample, arise, close, closely, compound, conversion, convert, customary, deliver, ensure, entered, equivalent, estimable, governed, indemnification, indenture, monitor, National, performed, Postemployment, prospective, ranging, relating, representing, repurchased, respond, restructure, separating, soravtansine, stated, subsidiary, trademark, transitioning, transportation, Trust, trustee, unpaid, varying, weather, Wilmington, work, worked